Hepatocellular carcinoma secondary prevention: Difference between revisions
No edit summary |
Mahshid |
||
| Line 13: | Line 13: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Hepatology]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Surgery]] | |||
Revision as of 02:00, 27 November 2017
|
Hepatocellular carcinoma Microchapters |
|
Differentiating Hepatocellular carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hepatocellular carcinoma secondary prevention On the Web |
|
American Roentgen Ray Society Images of Hepatocellular carcinoma secondary prevention |
|
Risk calculators and risk factors for Hepatocellular carcinoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
Secondary prevention strategies following hepatocellular carcinoma include retinoids, Intra-arterial iodine-131-lipiodol embolization, and adoptive adjuvant immunotherapy.[1]
Secondary Prevention
Secondary prevention strategies following hepatocellular carcinoma include retinoids, Intra-arterial iodine-131-lipiodol embolization, and adoptive adjuvant immunotherapy.
References
- ↑ Colombo M, Donato MF (2005). "Prevention of hepatocellular carcinoma". Semin Liver Dis. 25 (2): 155–61. doi:10.1055/s-2005-871195. PMID 15918144.